Navigation Links
SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
Date:12/16/2008

BOTHELL, Wash., Dec. 16 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext: DDD) today announced that Daniel O. Wilds had resigned as Chief Executive Officer of the Company and as a member of its Board of Directors effective December 12, 2008.

Michael N. Taglich, Chairman of the Board of SCOLR Pharma, said, "On behalf of the Board of Directors and SCOLR's entire organization, I would like to thank Dan for his more than five years of vision and leadership. We are focused on advancing our extended release CDT(R) ibuprofen towards an FDA submission in 2009. We believe we are well positioned to achieve advantageous alliances with major pharmaceutical companies and other potential partners. We continue to manage our cash to maximize resources appropriately in the current environment. Our development work continues on a positive track and I believe that advancing our core proprietary clinical programs will result in increased shareholder value and make us a stronger organization."

The Company will be managed by its existing executive management team on an interim basis.

About SCOLR Pharma

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.368.1050 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995,including without limitation statements related to the timing and success of our products under development and the potential for alliances. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to successfully develop new formulations and complete research and development, including pre-clinical and clinical studies, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products and we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

    Contacts:
    Investor Relations:
    Cameron Associates
    Kevin McGrath
    212.245.4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
2. SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern
3. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
4. Why Do Drugs Cost So Much? and why are we so darn sick?: New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health
5. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
6. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
7. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
8. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
9. Go Healthy Announces Agreement in Principle With Dynamic Investments LTD for a Rule 144-A $100 Million Covered Bond Placement
10. Zeus Announces Product-Line Expansion with Insulated PEEK(TM) Wire
11. White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 2016 , ... SPH Analytics announced today that DeKalb ... solutions, MDinsight® and IndiGO®, for its primary care clinicians. The 3-year partnership brings ... contract were not disclosed. , As the healthcare market moves towards quality-based outcomes, ...
(Date:2/11/2016)... ... February 11, 2016 , ... Student-doctors from Western University of ... Program Tuesday, February 9, taking one of the final steps in their medical ... positions across the country. Of the 103 student-doctors who comprise the College of ...
(Date:2/11/2016)... Whippany, New Jersey (PRWEB) , ... February 11, 2016 , ... ... invited to a free CEU seminar titled, “Stroke Management: Time to Act, Time to ... Senior Housing Community in Whippany, N.J. The presenter is Vishal Chedda, president of ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... experience performing a wide range of cosmetic procedures. Along with performing procedures, the ... efficiency and results of many cosmetic procedures. One of the most common procedures ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Florida Hospital presents ... take on the St. Louis Blues at the Amalie Arena. The puck drops at ... walk-through heart exhibit, the MEGA Heart, prior to the game. The MEGA Heart will ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... YORK , Feb. 11, 2016 ... - Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key ... Testing. - Molecular Diagnostics in Genetic Testing. ... Molecular Diagnostics Markets. - Over-the-Counter Diagnostic Products World ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology: